NYSE Arca · PRTOHealthcareBiotechnology

RCN Pareto Strategic Allocation ETF news

$27.18−1.42%

Close Sep 28, 2026 · split-adjusted

Articles · 30 days0English, de-duplicated

Positive0

Neutral0

Negative0

About RCN Pareto Strategic Allocation ETF

No recent articles focused on RCN Pareto Strategic Allocation ETF.

Also mentions PRTO

Articles that tag PRTO but are mainly about other companies.

Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC

GlobeNewswire Inc.May 15, 7:00 AM ET▲ Positive

The company announced positive clinical trial results with durable 12-month efficacy data (55% CR rate), excellent safety profile (no Grade 3+ adverse events), and clear regulatory pathway forward with planned registrational trial initiation in 2H 2026 and BLA submission in 2H 2027. These milestones support advancement toward potential commercialization.

Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology